Skip to main content
    E

    Eledon Pharmaceuticals Inc (ELDN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.97
    -0.15 (-6.86%)

    Market Cap: $178.63M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Eledon Pharmaceuticals Inc (ELDN) Financials: Revenue, Profit and Cash Flow

    Updated Nov 12, 2026. Financial statements from company filings, amounts in US dollars.

    Eledon Pharmaceuticals reported revenue of $0 for the fiscal year ended Dec 31, 2025. That year, net income was -$45.62M, operating cash flow was -$62.34M and free cash flow was -$62.34M. The quarter ended Sep 30, 2026 had revenue of $0 and net income of -$3.93M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2025, with an operating loss of $83.25M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2025$0N/AN/AN/AN/A
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Dec 2016$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2016 to Dec 2025

    Income Statement

    In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Research and development$66.27M$51.96M$30.31M$27.08M$23.73M$6.13M$8.13M$6.82M$2.02M$3.19M
    Operating income-$83.25M-$70.58M-$43.00M-$88.43M-$36.87M-$18.46M-$16.05M-$14.06M-$13.12M-$5.13M
    Net income-$45.62M-$36.18M-$116.54M-$87.97M-$34.51M-$22.81M-$16.01M-$14.06M-$13.12M-$5.66M
    EBITDA-$45.58M-$35.75MN/A-$87.59M-$36.66MN/A-$15.83M-$14.05M-$13.10M-$5.09M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Revenue$0$0$0$0$0$0$0$384.00K$0$0$0$0
    Gross profit$0$0$0N/A$0$0$0-$88.00K$0$0$0-$94.00K
    Operating income-$21.67M-$22.87M-$21.18M-$21.48M-$19.07M-$24.73M-$17.96M-$24.70M-$20.51M-$14.50M-$10.87M-$10.34M
    Net income-$3.93M-$31.63M-$39.02M-$10.45M-$17.46M-$11.22M-$6.50M-$44.62M$76.97M-$44.91M-$23.63M-$30.10M
    Last 12 quarters

    Balance Sheet

    As of Dec 2025, cash and equivalents exceeded short-term debt of $358.00K by $22.45M.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Total assets$169.01M$177.41M$89.07M$92.79M$170.55M$197.19M$10.93M$17.03M$20.89M$1.20M
    Current assets$135.69M$143.73M$56.13M$59.52M$88.35M$115.63M$9.97M$14.28M$19.00M$1.15M
    Cash and equivalents$22.81M$20.55M$4.61M$56.41M$84.83M$114.19M$8.79M$12.97M$17.23M$1.10M
    Total liabilities$32.23M$59.27M$81.86M$8.61M$6.55M$6.59M$1.47M$2.53M$1.44M$3.90M
    Short-term debt$358.00K$314.00K$383.00K$363.00K$369.00K$144.00K$180.00KN/AN/A$3.45M
    Shareholder equity$81.08M$62.45M-$48.49M$84.18M$164.00M$190.60M$9.46M$14.49M$19.45M-$2.70M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Total assets$106.64M$126.09M$146.67M$169.01M$129.86M$144.91M$161.31M$177.41M$114.58M$120.48M$80.82M$125.89M
    Total liabilities$36.83M$54.06M$46.21M$87.92M$38.80M$38.88M$46.73M$59.27M$38.52M$128.98M$95.55M$42.48M
    Cash and equivalents$6.88M$6.80M$6.15M$22.81M$3.67M$5.74M$8.50M$20.55M$6.75M$26.04M$5.66M$4.61M
    Shareholder equity$30.80M$33.01M$44.76M$81.08M$35.36M$50.33M$58.89M$118.14M$76.06M-$8.50M-$14.73M$83.42M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2025.

    Annual

    Line itemDec 2025Dec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017Dec 2016
    Operating cash flow-$62.34M-$47.27M-$39.53M-$28.42M-$28.91M-$15.21M-$13.86M-$11.89M-$14.94M-$4.92M
    Capital expenditures$0$0$0$0$0$0$0$0$0$9.00K
    Free cash flow-$62.34M-$47.27M-$39.53M-$28.42M-$28.91M-$15.21M-$13.86M-$11.89M-$14.94M-$4.93M
    Dividends paidN/AN/AN/AN/AN/A$25.00KN/AN/AN/AN/A
    Share repurchasesN/AN/AN/AN/A$450.00K$0N/AN/AN/AN/A
    Investing cash flow$10.79M-$70.31M-$45.29M$0$0$11.04M$0$0$23.26M$1.00K
    Financing cash flow$53.81M$133.52M$33.02M$0-$449.00K$109.58M$9.68M$7.56M$7.87M$2.93M
    Fiscal years ended Dec 2016 to Dec 2025

    Quarterly

    Line itemSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023
    Operating cash flow-$18.98M-$22.68M-$22.61M-$14.09M-$14.48M-$17.71M-$16.06M-$18.99M-$11.77M-$7.77M-$8.74M-$9.13M
    Free cash flowN/AN/A-$22.61M-$14.09M-$14.48M-$17.71M-$16.06M-$18.99M-$11.77M-$7.77M-$8.74M-$9.13M
    Last 12 quarters

    Frequently Asked Questions About ELDN

    What is Eledon Pharmaceuticals' annual revenue?

    Eledon Pharmaceuticals reported revenue of $0 for the fiscal year ended Dec 31, 2025.

    Is Eledon Pharmaceuticals profitable?

    No. Eledon Pharmaceuticals reported net income of -$45.62M for the fiscal year ended Dec 31, 2025.

    How much free cash flow does ELDN generate?

    For the fiscal year ended Dec 31, 2025, operating cash flow of -$62.34M minus capital expenditures of $0 produced free cash flow of -$62.34M.

    How much debt does Eledon Pharmaceuticals have?

    The balance sheet dated Dec 31, 2025 reported short-term debt of $358.00K and cash and equivalents of $22.81M.